AAAAAA

   
Results: 1-10 |
Results: 10
Prostate-specific membrane antigen (PSMA): Current benefits and future value
Authors: Elgamal, AAA Holmes, EH Su, SL Tino, WT Simmons, SJ Peterson, M Greene, TC Boynton, AL Murphy, GP
Citation: Aaa. Elgamal et al., Prostate-specific membrane antigen (PSMA): Current benefits and future value, SEM SURG ON, 18(1), 2000, pp. 10-16
Statistical modeling and analyses of a base-specific Salmonella mutagenicity assay
Authors: Piegorsch, WW Simmons, SJ Margolin, BH Zeiger, E Gidrol, XM Gee, P
Citation: Ww. Piegorsch et al., Statistical modeling and analyses of a base-specific Salmonella mutagenicity assay, MUT RES-GTE, 467(1), 2000, pp. 11-19
Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients
Authors: Murphy, GP Tjoa, BA Simmons, SJ Rogers, MK Kenny, GM Jarisch, J
Citation: Gp. Murphy et al., Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients, PROSTATE, 43(1), 2000, pp. 59-62
Use of artificial neural networks in evaluating prognostic factors determining the response to dendritic cells pulsed with PSMA peptides in prostate cancer patients
Authors: Murphy, GP Snow, P Simmons, SJ Tjoa, BA Rogers, MK Brandt, J Healy, CG Bolton, WE Rodbold, D
Citation: Gp. Murphy et al., Use of artificial neural networks in evaluating prognostic factors determining the response to dendritic cells pulsed with PSMA peptides in prostate cancer patients, PROSTATE, 42(1), 2000, pp. 67-72
An error bound for reduced-state Viterbi decoding of TCM codes
Authors: Simmons, SJ
Citation: Sj. Simmons, An error bound for reduced-state Viterbi decoding of TCM codes, IEEE COMM L, 3(9), 1999, pp. 266-268
ACI susceptibility of reduced-state decoding for CPM
Authors: Simmons, SJ
Citation: Sj. Simmons, ACI susceptibility of reduced-state decoding for CPM, IEEE COMM L, 3(11), 1999, pp. 305-307
Follow-up evaluation of a phase II prostate cancer vaccine trial
Authors: Tjoa, BA Simmons, SJ Elgamal, A Rogers, M Ragde, H Kenny, GM Troychak, MJ Boynton, AL Murphy, GP
Citation: Ba. Tjoa et al., Follow-up evaluation of a phase II prostate cancer vaccine trial, PROSTATE, 40(2), 1999, pp. 125-129
GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial
Authors: Simmons, SJ Tjoa, BA Rogers, M Elgamal, A Kenny, GM Ragde, H Troychak, MJ Boynton, AL Murphy, GP
Citation: Sj. Simmons et al., GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial, PROSTATE, 39(4), 1999, pp. 291-297
Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment
Authors: Murphy, GP Tjoa, BA Simmons, SJ Ragde, H Rogers, M Elgamal, A Kenny, GM Troychak, MJ Salgaller, ML Boynton, AL
Citation: Gp. Murphy et al., Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment, PROSTATE, 39(1), 1999, pp. 54-59
Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease
Authors: Murphy, GP Tjoa, BA Simmons, SJ Jarisch, J Bowes, VA Ragde, H Rogers, M Elgamal, A Kenny, GM Cobb, OE Ireton, RC Troychak, MJ Salgaller, ML Boynton, AL
Citation: Gp. Murphy et al., Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease, PROSTATE, 38(1), 1999, pp. 73-78
Risultati: 1-10 |